# Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/LEGN/legend-biotech-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-66027e2e
Ticker: LEGN
Company: Legend Biotech Corporation
Source: Legend Biotech Corporation
Published: 2025-12-17 13:00 EST
## Summary

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today...

## Article Body
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14 th , 2026, at 9:00 a.m. PT.

The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend’s website. The webcast replay will be available approximately 48 hours after the webcast.

ABOUT LEGEND BIOTECH

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI ® , a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Headquartered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn .

INVESTOR CONTACT: Jessie Yeung Tel: (732) 956-8271 jessie.yeung@legendbiotech.com

PRESS CONTACT: Alexandra Ventura Tel: (732) 850-5598 media@legendbiotech.com
## Recent Company News
- 2026-07-28 12:00 EST — [Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results](https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-second-quarter-2026-results-3744bba0) — Source: Legend Biotech Corporation
- 2026-07-27 10:00 EST — [Legend Biotech Announces CEO Transition](https://biopharmsignal.com/news/LEGN/legend-biotech-announces-ceo-transition-6f26346e) — Source: Legend Biotech Corporation
- 2026-06-18 01:21 EST — [Legend Biotech Corporation Announces Pricing of Public Offering](https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-pricing-of-public-offering-c0ab1d0b) — Source: Legend Biotech Corporation
- 2026-06-17 20:29 EST — [Legend Biotech Corporation Announces Proposed Public Offering](https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-proposed-public-offering-3615b70e) — Source: Legend Biotech Corporation
- 2026-06-15 12:00 EST — [Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma](https://biopharmsignal.com/news/LEGN/legend-biotech-establishes-clinical-proof-of-concept-for-lb2501-a-potential-firs-fb89efa6) — Source: Legend Biotech Corporation
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)